Sunday, October 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 23, 2026

Warsh's Fed 'regime change' may require patience, consensus

View original at finance.yahoo.com
Warsh's Fed 'regime change' may require patience, consensus (Bloomberg) -- Kevin Warsh has vowed to usher in “regime change” as the new chair of the Federal Reserve, but Fed watchers say there are limits to how much he can revamp on his own — and that even in areas where he can make sweeping reform, it might be smarter…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump has made it no secret that he expects Warsh to lower interest rates

    60% confidence
  • If lowering rates is Warsh's top priority, he will have a strong incentive to avoid alienating FOMC members and to curry goodwill

    60% confidence
  • Warsh has vowed to usher in 'regime change' as the new Federal Reserve chair

    60% confidence
  • With inflation accelerating and the labor market stabilizing, FOMC policymakers are comfortable keeping rates on hold

    60% confidence
  • Warsh has vowed to keep monetary policy independent from politics

    60% confidence
  • One of Warsh's primary tasks will be building FOMC consensus to lower interest rates when appropriate

    60% confidence
  • Some FOMC policymakers are pushing for the Fed to signal its next move is just as likely to be a rate hike as a rate cut

    60% confidence
  • Warsh has long been an advocate for shrinking the Fed's asset portfolio

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com